Corbus Pharmaceuticals, Inc.
100 River Ridge Drive
Norwood
Massachusetts
02062
United States
Tel: 617-963-0100
Fax: 617-663-6085
Website: http://www.corbuspharma.com/
105 articles with Corbus Pharmaceuticals, Inc.
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
3/7/2023
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2022.
-
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
3/6/2023
Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors.
-
Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/2/2023
Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 33rd Annual Healthcare Conference.
-
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/10/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, is presenting new preclinical data for CRB-601 today in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston.
-
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/8/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, today provided a corporate update and reported financial results for the third quarter of 2022.
-
PD-L1 expression is not the static, “yes/no” predictor of tumor response for which researchers hoped. Surface Oncology, Immutep and Corbus are each taking a different approach to immuno-oncology.
-
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
9/26/2022
Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/9/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
-
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
5/11/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers in Cancer Immunotherapy Conference in New York, NY.
-
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
-
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
3/11/2022
Corbus Pharmaceuticals Holdings, Inc. today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
3/8/2022
Corbus Pharmaceuticals Holdings, Inc., an immunology company, provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.
-
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
12/7/2021
Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose.
-
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11/11/2021
Corbus Pharmaceuticals Holdings, Inc. will participate in a fireside chat at the Jefferies London Healthcare Conference being held virtually and in person November 16-19, 2021.
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.
-
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).